Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Recipient : Avior Bio
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the agreement, Hillstream aims to acquire a clinical stage asset, AV104 (nalmefene), an opioid antagonist, but first it intends to seek approval in an orphan disease for the treatment of moderate to severe cholestatic pruritis with primary biliar...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 09, 2023
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Recipient : Avior Bio
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HSB-1216, is a novel and potent inducer of a powerful mechanism involving iron-mediated cell death. It is an emerging new anti-cancer mechanism, resulting in iron mediated cell death (IMCD) of drug resistant cancers.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HSB-510
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HSB-510 is a novel highly targeted bifunctional inhibitor encapsulated in quatramer with single digit nanomolar IC 50 against PI3-Kδ and HDAC6, which is also known to downregulate MYC, a highly pursued and yet undruggable cancer target.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2023
Lead Product(s) : HSB-510
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : Applied Biomedical Science Institute
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims to develop proprietary multi-format biologics, including bi-specific antibodies, and antibody drug conjugates (ADCs) by leveraging ABSI's technology for human antibodies targeting novel HER2 and HER3 Conformational Epitopes.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 07, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Applied Biomedical Science Institute
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Thinkequity
Deal Size : $2.6 million
Deal Type : Public Offering
Hillstream BioPharma Announces Pricing of Public Offering
Details : The Company intends to use the net proceeds from the offering for the advancement of HSB-1216, a novel and potent inducer of a powerful mechanism involving iron-mediated cell death, and the development of other product candidates in the Company’s pipel...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 27, 2023
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Thinkequity
Deal Size : $2.6 million
Deal Type : Public Offering
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : OncoBay Clinical
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, OncoBay will provide comprehensive clinical and regulatory support for the clinical development program for Hillstream's lead drug HSB-1216, which targets ferroptosis, an emerging new anti-cancer mechanism, resulting in IMCD of drug ...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 13, 2023
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : OncoBay Clinical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Applied Biomedical Science Institute
Deal Size : Undisclosed
Deal Type : Agreement
Details : Hillstream has the option to license technology for HER2 and HER3 Conformational Domain Bridging Epitopes in antibodies to develop proprietary multi-format biologics against drug resistant cancers including HER2-positive metastatic breast, gastric, lung ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 13, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Applied Biomedical Science Institute
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Thinkequity
Deal Size : $2.6 million
Deal Type : Public Offering
Hillstream BioPharma Announces Closing of Public Offering of Common Stock
Details : The Company intends to use the net proceeds for the advancement of its lead drug candidate HSB-1216, which targets ferroptosis, an emerging new anti-cancer mechanism, and the development of other product candidates in the Company’s pipeline.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 05, 2023
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Thinkequity
Deal Size : $2.6 million
Deal Type : Public Offering
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Dana-Farber Cancer Institute
Deal Size : Undisclosed
Deal Type : Agreement
Details : Dana-Farber has granted under an exclusive option agreement to Hillstream Biopharma Inc., to develop anti-MUC1-C antibodies to selectively deliver Hillstream’s Quatramer-based lead candidate HSB-1216 targeting CSC by the induction of ferroptosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 31, 2023
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Dana-Farber Cancer Institute
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Thinkequity
Deal Size : $15.0 million
Deal Type : Public Offering
Hillstream BioPharma Announces Pricing of Initial Public Offering
Details : The net proceeds from the initial public offering will be used to advance the Company’s product candidate HSB-1216 through pre-clinical activities, completion of Phase 1 studies and manufacturing, to advance the Company’s candidate HSB-888 through pr...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
November 01, 2022
Lead Product(s) : Salinomycin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Thinkequity
Deal Size : $15.0 million
Deal Type : Public Offering